Dataset Information

Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis.

ABSTRACT: Background. Although the benchmark in the treatment of rheumatoid arthritis remains methotrexate, only 70% of patients respond. Thus, there is a need for predictive biomarkers. This study planned to evaluate serum levels of myeloid progenitor inhibitory factor-1 (MPIF-1) and monocyte chemoattractant protein 2 (MCP-2)-as biomarkers. Methods. Patients with rheumatoid arthritis (RA) having high disease activity (DAS28-3v???5.1) were treated with oral methotrexate (MTX) for 12 weeks. Disease activity was measured by DAS28-3v (Modified Disease Activity Score 3 variables). Serum samples were stored at baseline and 12 weeks. Results. This study included 46 patients (F?:?M = 35?:?11) having mean (±SD) age of 42.6 ± 11.3?yrs, disease duration of 4.7 ± 4.5?yrs, and DAS28-3v of 6.1 ± 0.8. Serum MPIF1 was elevated in patients compared to controls (1636.7 ± 1009.7, 441.2 ± 173.8?pg/mL, P < 0.001), but there was no difference in MCP2 levels (31.4 ± 11.9, 33.8 ± 24.0?pg/mL). Baseline MPIF-1 level was lower in good responders (?DAS28-3v???1.2, N = 9) compared to poor responders (?DAS28-3v?

SUBMITTER: Dhir V

PROVIDER: S-EPMC3886573 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis.

Dhir Varun V Sandhu Amit A Gupta Nidhi N Dhawan Veena V Sharma Shefali S Sharma Aman A

ISRN inflammation 20131224

Background. Although the benchmark in the treatment of rheumatoid arthritis remains methotrexate, only 70% of patients respond. Thus, there is a need for predictive biomarkers. This study planned to evaluate serum levels of myeloid progenitor inhibitory factor-1 (MPIF-1) and monocyte chemoattractant protein 2 (MCP-2)-as biomarkers. Methods. Patients with rheumatoid arthritis (RA) having high disease activity (DAS28-3v ≥ 5.1) were treated with oral methotrexate (MTX) for 12 weeks. Disease activit ...[more]

PMID: 24455421

Similar Datasets

Project description:BackgroundRheumatoid arthritis (RA) is a significant issue, particularly in bone health problems, because it can prolong diseases like secondary osteoporosis. Subsequently, the anchor of drug therapy for RA is methotrexate (MTX), which also has the potential to reduce the risk of secondary osteoporosis.ObjectiveThis study aims to examine the effect of MTX on calcium levels, an important parameter for monitoring bone health and the risk of secondary osteoporosis in patients with RA.MethodsA retrospective study was carried out by collecting data from the medical records of patients, which included demographic and patient characteristics, treatment data (drug and dosage), duration of treatment, and calcium levels. All patients were diagnosed with RA and fell within the age range of 18 to 59 years. Additionally, the effectiveness of MTX therapy was compared with other treatments, categorizing patient data accordingly. Statistical analyses, such as χ2 and ordinal regression, using IBM-SPSS Statistics version 25 (IBM-SPSS Inc, Armonk, New York) were used to establish associations between MTX treatment and calcium levels, reporting odds ratio and 95% CI values.ResultsThe data consisted of 123 patients with RA, comprising 99 who had a history of MTX use for more than 6 months and 24 who either did not use MTX or used it for <6 months. The majority of patients were women and their ages ranged between 40 and 59 years. MTX monotherapy was the most used with a dose range of 7.5 to 15 mg. Furthermore, this study observed that patients treated with MTX between 7.5 and 15 mg have lower serum calcium levels than those who received 17.5 to 25 mg (P = 0.022; odds ratio = 5.663; 95% CI, 0.251-3.218). Most patients with RA using MTX maintained normal calcium levels. No significant differences were observed between single MTX therapy and combination therapy.ConclusionsAlthough further investigation is needed, this study showed the potential properties of MTX in maintaining patients' serum calcium levels, which may help to reduce the risk of secondary osteoporosis in patients with RA.

Dataset Information

Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis.

Publications

Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets